Both companies may succeed in this industry.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...

Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock ...

The pill version of Wegovy seems to work just as well as the injectable form, but there are some key differences between the ...

Dr. Reddy’s has received an approval from India’s drug regulator to manufacture and sell the generic version of diabetes drug ...

The patent for Semaglutide, the active ingredient in Novo Nordisk's drugs Wegovy and Ozempic, expires in March 2026, allowing ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features. Reclaim your full access. Click below to renew.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Indian drugmaker Dr Reddy's , which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval from the country's drug regulator to manufacture and ...

India, meanwhile, witnessed the launch of three global obesity blockbusters last year—Mounjaro, Wegovy, and Ozempic (approved for type-2 diabetes but widely used off-label for obesity). All three have ...

DWF looks at escalating safety risks and the growing exposure for professional indemnifiers in the UK & Ireland ...